Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort

AIDS

Volumn 27, Issue 2, 2013, Pages 191-201

  Thio, Chloe L ^a   Smeaton, Laura ^b   Saulynas, Melissa ^a   Hwang, Hyon ^a   Saravan, Shanmugam ^c   Kulkarni, Smita ^d   Hakim, James ^e   Nyirenda, Mulinda ^f   Iqbal, Hussain S ^c   Lalloo, Umesh G ^g   Mehta, Anand S ^h   Hollabaugh, Kimberly ^b   Campbell, Thomas B ⁱ   Lockman, Shahin ^j   Currier, Judith S ^k  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^d NATIONAL AIDS RESEARCH INSTITUTE   (India)

^e UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^f UNIVERSITY OF MALAWI   (Malawi)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

coinfection; global; hepatitis B virus; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BODY MASS; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; EPIDEMIC; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEGRO; OUTCOME ASSESSMENT; POVERTY; PRIORITY JOURNAL; SCREENING; SINGLE DRUG DOSE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COINFECTION; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; VIRAL LOAD;

EID: 84872380490     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835a9984     Document Type: Article

References (24)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (1 Suppl):S6-S9.
2. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM, Hepatitis B. C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007; 22:1510-1518.
3. Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IL, Munthali C, et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect 2008; 57:72-77.
4. Diop-Ndiaye H, Toure-Kane C, Etard JF, Lo G, Diaw P, Ngom-Gueve NF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008; 80:1332-1336.
5. Lee HC, Ko NY, Lee NY, Chang CM, Ko WC. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000-2005: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008; 107:404-411.
6. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
7. Thio CL, Seaberg EC, Skolasky RL, Phair J, Bisscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360:1921-1926.
8. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et al. Hepatitis B virus co-infection impacts baseline HIV parameters and HAART-related hepatotoxicity risk in an HIV-infected Nigerian cohort. Clin Infect Dis 2009; 49:1268-1273.
9. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med 2012; 9:e1001290.
10. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363:1499-1509.
11. Mehta AS, Long RE, Communale MA, Wang M, Rodemich L, Krakover J, et al. Increased levels of galactose-deficient antigal IgG in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol 2008; 82:1259-1270.
12. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasa-duesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-870.
13. Division of AIDS. Table for grading the severity of adult and pediatric adverse events. (2009). http://rsc.tech-res.com/Docu ment/ safetyandpharmacovigilance/Table-for-Grading-Severi ty-of-Adult-Pediatric- Adverse-Events.pdf. [Accessed June 2012]
14. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378:73-85.
15. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
16. Deng L, Tang H. Hepatitis B virus drug resistance to current nucleos(t)ide analogs: mechanisms and mutation sites. Hepatol Res 2011; 41:1017-1024.
17. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47:1479-1485.
18. Kirishima T, Okanoue T, Daimon Y, Itoh Y, Nakamura H, Morita A, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol 2002; 37:259-265.
19. Ohishi W, Shirakawa H, Kawakami Y, Kimura S, Kamlyasu M, Tazuma S, et al. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping. J Med Virol 2004; 72:558-565.
20. Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ. Mutations associated with lamivudine-resis-tance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretro-viral therapy in HBV and HIV co-infected South African patients. J Med Virol 2007; 79:1650-1654.
21. Gobel T, Erhardt A, Herwig M, Poremba C, Baidus SE, Sagir A, et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. J Med Virol 2011; 83:968-973.
22. Stabinski L, Reynolds SJ, Ocama P, Laeyendecker O, Ndyanabo A, Kiggundu V, et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther 2011; 16:405-411.
23. Krarup H, Andersen S, Madsen PH, Chritensen PB, Laursen AL, Bentzen-Petersen A, et al. HBeAg and not genotypes predicts viral load in patients with hepatitis B in Denmark: a nationwide cohort study. Scand J Gastroenterol 2011; 46:1484-1491.
24. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000; 7:258-267.